Truist upgrades Biogen to Buy, raises target to $235

0 min read     Updated on 13 Jul 2026, 05:23 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Truist Securities analyst Srikripa Devarakonda upgraded Biogen Inc from Hold to Buy, increasing the price target from $190 to $235. Biogen shares closed at $199.15 on Friday.

powered bylight_fuzz_icon
45484874

*this image is generated using AI for illustrative purposes only.

Truist Securities analyst Srikripa Devarakonda has upgraded Biogen Inc from Hold to Buy, raising the price target to $235 from $190. The rating change reflects a more positive outlook on the stock's performance potential. Biogen shares closed at $199.15 on Friday.

Rating and Target Changes

The upgrade moves Biogen out of a neutral stance, signaling confidence in future gains. The new price target of $235 represents a significant increase from the previous $190 level.

Metric Previous New
Rating Hold Buy
Price Target $190 $235

What specific factors or upcoming catalysts drove Truist Securities to shift its outlook to positive?

How might this upgrade influence other analysts' ratings and overall market sentiment for Biogen?

What are the expected timelines for Biogen to reach the new $235 price target?

like20
dislike

Morgan Stanley lowers Biogen price target to $222

0 min read     Updated on 09 Jul 2026, 01:27 AM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Morgan Stanley analyst Matthew Harrison maintained an Equal-Weight rating on Biogen (NASDAQ: BIIB) while lowering the price target to $222 from $224, signaling a more cautious outlook on the stock's valuation.

powered bylight_fuzz_icon
44997330

*this image is generated using AI for illustrative purposes only.

Morgan Stanley analyst Matthew Harrison has maintained an Equal-Weight rating on Biogen (NASDAQ: BIIB) and lowered the price target to $222 from $224. This adjustment reflects a revised outlook on the company's valuation and market position.

Rating and Target Details

The firm's decision to decrease the price target suggests a more cautious stance on Biogen's near-term performance. The previous target of $224 has been adjusted downward to $222.

Metric Value
Rating Equal-Weight
Previous Price Target $224
New Price Target $222

Analyst Perspective

Matthew Harrison of Morgan Stanley continues to hold a neutral view on the stock, maintaining the Equal-Weight status. The revised price target indicates that the analyst sees limited upside potential for Biogen in the current market environment.

What specific market factors are driving the cautious near-term outlook for Biogen?

How might Biogen's upcoming product pipeline influence future analyst ratings?

What impact could competitor performance have on Biogen's market position?

like16
dislike

More News on Biogen Inc